Trial Profile
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioma
- Focus Therapeutic Use
- 23 Apr 2015 New trial record